QUECTEL-WIRELESS
26.6.2024 13:01:27 CEST | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, announced the launch of the FLM263D standalone Wi-Fi module that supports Alexa Connect Kit (ACK) SDK for Matter, enabling IoT devices to connect seamlessly with Matter compliant controllers including Amazon Alexa, Google Home, Samsung SmartThings, and Apple HomeKit.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240626747648/en/
Quectel unveils FLM263D Wi-Fi module: Pioneering seamless connectivity with ACK SDK for Matter (Photo: Business Wire)
Matter stands as a pivotal standard in smart home communication, tackling the persistent challenges of compatibility and fragmentation within the sector by enabling direct communication between smart devices. Governed by the Connectivity Standards Alliance (CSA), Matter devices undergo a stringent certification process to ensure secure, reliable, and universally interoperable connections. Adherence to this certification is paramount for all Matter-compliant products, fostering a unified communication framework and enhancing user experiences.
“We created ACK to make it simpler for device makers to build smart home devices with a fully-managed service without having deep expertise in multiple wireless protocols, complex cloud connectivity, and the necessary maintenance of cloud infrastructure. We are excited about this launch because Quectel’s FLM263D adds to ACK's portfolio of available solutions and offers more choices for device makers,” says Ben McInnis, Director, Smart Home, Amazon.
“Revolutionizing connectivity in the smart home landscape, our latest FLM263D module sets a new standard for seamless integration,” commented Norbert Muhrer, President and CSO, Quectel Wireless Solutions. “It also empowers developers with robust support for the ACK SDK for Matter, ensuring unparalleled interoperability and innovation in the IoT ecosystem.”
The FLM263D module is a 2.4GHz single band Wi-Fi 6 module, featuring a high-performance processor with a frequency of up to 320MHz. This innovative module boasts support for IEEE 802.11b/g/n/ax protocol and BLE 5.2, paired with built-in 512KB SRAM and 4MB flash for optimal performance. Furthermore, it meets rigorous security standards, including secure boot and mbed TLS encryption, ensuring robust protection for connected devices.
The FLM263D offers support for device certifications such as Works with Alexa (WWA) and features such as Matter Simple Setup (MSS). MSS allows end-users to seamlessly connect Matter-compliant smart home devices to Alexa with zero-touch setup, while WWA instils consumer confidence when buying on Amazon.
FLM263D offers five GPIO interfaces that can alternatively function as PWM or I2C communication channels. Designed with an LCC form factor, built-in PCB antenna, measuring a mere 17.3mm × 15.0mm × 2.8mm, and with an operating temperature range of -40°C to +105°C, 3.0~3.6V power supply, the FLM263D is perfectly suited for smart lighting applications, especially smart bulbs.
Additional modules will be rolled out very soon to expand the scope of Quectel offerings to include smart switches, smart plugs, and other smart household applications.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240626747648/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 15:07:00 CEST | Press release
Initial planning calls for Data Sciences Division to focus efforts in cyber secure infrastructure with dedication in fintech and patented Information Data Exchange® (IDE®) Management will harness its API Media acquisition, robust patent portfolio, ADIO® Inaudible Tones, WiSA® and Dolby® partnerships to establish worldwide acoustic industry standards in high-definition wireless transmission, spatial-audio control and interoperability Plan includes API media’s stand-alone and renewed execution of WiSA semiconductor and software modules strategy with an R&D effort targeted to new robotic and drone applications Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™,
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 14:50:00 CEST | Press release
First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs)at the 2026 EADV SymposiumThe vast majority of patients achieving EASI50 at Week 8 and continuing double-blind, as needed treatment with Opzelura® (ruxolitinib) cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 (a ≥75% improvement in the Eczema Area and Severity Index score from baseline) and 70.6% achieving IGA-TS (Investigator’s Global Assessment Treatment Success)Data support Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU), feedback expected in 1H 2026 Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with mode
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release
“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom